Antibiotic Treatment Trial in Acute Coronary Syndrome
Key facts
- Where
- Tampere, FinnországSee the site
- Phase
- 4. fázis
Where in Finnország
- TAYS Sydaenkeskus OyTampere, FinnországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- TAYS Sydaenkeskus Oy
- Trial code
- EU 2025-522136-14-00
- Record updated
- 2025. augusztus 27.
- Original description
To assess whether the number of clinical endpoints (MACCE) can be reduced by antibiotic treatment, targeting mainly bacteria that have in previous studies been shown to be involved in complex atherosclerotic plaques, such as those found in patients suffering from acute myocardial infarction.Read full original descriptionShow less
To assess whether the number of clinical endpoints (MACCE) can be reduced by antibiotic treatment, targeting mainly bacteria that have in previous studies been shown to be involved in complex atherosclerotic plaques, such as those found in patients suffering from acute myocardial infarction.
Inclusion: Clinically diagnosed ST-elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI); Invasive strategy has been chosen, i.e. angiography is performed; Age ≥18 years; Informed consent has been obtained; at least 3 of following high risk criteria are met (hypertension, DM, moderate renal insufficiency eGFR<60ml/min, peripheral arterial disease ASO, multivessel coronary artery disease, previous myocardial infraction, previous stroke or TIA).
Exclusion: On-going methotrexate medication; On-going antibiotic therapy; Clinical diagnosis of Takotsubo syndrome; Severe valvular disease; On-going bleeding or very high bleeding risk; Severe allergy to contrast agents or ASA; Allergy to cephalosporin; Cardiogenic shock; Pregnancy; Probable finding of SCAD (spontaneous coronary dissection); Definite coronary embolism; < 1 year life expectancy.